MA26511A1 - Compositions pharmaceutiques comprenant de la 5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)-thiazolidine-2,4-dione et de l'insuline pour une methode de traitement. - Google Patents

Compositions pharmaceutiques comprenant de la 5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)-thiazolidine-2,4-dione et de l'insuline pour une methode de traitement.

Info

Publication number
MA26511A1
MA26511A1 MA25122A MA25122A MA26511A1 MA 26511 A1 MA26511 A1 MA 26511A1 MA 25122 A MA25122 A MA 25122A MA 25122 A MA25122 A MA 25122A MA 26511 A1 MA26511 A1 MA 26511A1
Authority
MA
Morocco
Prior art keywords
thiazolidine
dione
pyridyl
insulin
ethoxy
Prior art date
Application number
MA25122A
Other languages
English (en)
French (fr)
Inventor
Dr Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA26511A1 publication Critical patent/MA26511A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA25122A 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant de la 5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)-thiazolidine-2,4-dione et de l'insuline pour une methode de traitement. MA26511A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
MA26511A1 true MA26511A1 (fr) 2004-12-20

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25122A MA26511A1 (fr) 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant de la 5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)-thiazolidine-2,4-dione et de l'insuline pour une methode de traitement.

Country Status (30)

Country Link
EP (1) EP0999837A1 (enExample)
JP (1) JP2002504138A (enExample)
KR (1) KR20010013843A (enExample)
CN (1) CN1133431C (enExample)
AP (1) AP1287A (enExample)
AR (2) AR012997A1 (enExample)
AU (1) AU8216398A (enExample)
BG (1) BG104059A (enExample)
BR (1) BR9810444A (enExample)
CA (1) CA2294141A1 (enExample)
CO (1) CO4940454A1 (enExample)
DZ (1) DZ2521A1 (enExample)
EA (1) EA004800B1 (enExample)
GB (1) GB9712866D0 (enExample)
HU (1) HUP0003260A3 (enExample)
ID (1) ID23951A (enExample)
IL (1) IL133143A0 (enExample)
IN (1) IN189723B (enExample)
MA (1) MA26511A1 (enExample)
NO (1) NO996265L (enExample)
OA (1) OA11517A (enExample)
PE (1) PE104499A1 (enExample)
PL (1) PL343123A1 (enExample)
SK (1) SK179399A3 (enExample)
TR (1) TR199903095T2 (enExample)
TW (1) TW587937B (enExample)
UA (1) UA70299C2 (enExample)
UY (1) UY25050A1 (enExample)
WO (1) WO1998057636A1 (enExample)
ZA (1) ZA985237B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
HRP20010773B1 (en) 1999-04-23 2005-06-30 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
CA2503117C (en) 2002-11-08 2010-12-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1103590C (zh) * 1993-09-15 2003-03-26 三共株式会社 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
JPH11510508A (ja) * 1995-08-10 1999-09-14 ワーナー−ランバート・コンパニー インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法
PT859608E (pt) * 1995-09-18 2004-06-30 Ligand Pharm Inc Tratamento de niddm com agonistas de rxr

Also Published As

Publication number Publication date
PL343123A1 (en) 2001-07-30
NO996265D0 (no) 1999-12-17
AR015894A1 (es) 2001-05-30
PE104499A1 (es) 2000-01-13
EA004800B1 (ru) 2004-08-26
SK179399A3 (en) 2000-11-07
TW587937B (en) 2004-05-21
DZ2521A1 (fr) 2003-02-08
HUP0003260A3 (en) 2001-12-28
HUP0003260A2 (hu) 2001-05-28
CN1133431C (zh) 2004-01-07
WO1998057636A1 (en) 1998-12-23
CA2294141A1 (en) 1998-12-23
IL133143A0 (en) 2001-03-19
ID23951A (id) 2000-06-08
CN1260715A (zh) 2000-07-19
KR20010013843A (ko) 2001-02-26
AR012997A1 (es) 2000-11-22
TR199903095T2 (xx) 2000-08-21
NO996265L (no) 1999-12-17
BG104059A (en) 2000-10-31
OA11517A (en) 2004-02-04
AU8216398A (en) 1999-01-04
AP1287A (en) 2004-06-26
AP9901718A0 (en) 1999-12-31
IN189723B (enExample) 2003-04-19
JP2002504138A (ja) 2002-02-05
EA200000042A1 (ru) 2000-08-28
BR9810444A (pt) 2000-09-05
UY25050A1 (es) 2000-09-29
ZA985237B (en) 2000-02-17
CO4940454A1 (es) 2000-07-24
EP0999837A1 (en) 2000-05-17
GB9712866D0 (en) 1997-08-20
UA70299C2 (en) 2004-10-15

Similar Documents

Publication Publication Date Title
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
IL146111A0 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl) amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
IL136424A0 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
NO2009002I1 (no) 5-{4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl}tiazolidin-2,4-dionmaleat(salter/solvater)+glimepirid
DZ2521A1 (fr) Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l'insuline pour une méthode de traitement.
IL136381A0 (en) Hydrate of 5-[4-[2-(n- methyl-n-(2-(pyridil)amino) ethoxy]benzyl] thiazolidine-2,4- dione maleic acid salt
HUP0004070A3 (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
HUP0003397A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione for producing medicament useful in the treatment of polycystic ovary syndrome and gestational diabetes
AU2002343036A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2,4-dione and pharmaceutical compositions comprising the same
DE60212434D1 (de) Rosiglitazon-edisylate und ihre verwendung als antidiabetika
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
DK1349855T3 (da) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidin-2,4-dionmesylatsalt
GB0021784D0 (en) Novel pharmaceutical
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
HUP0301799A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide for treating diabetes mellitus, process for preparation thereof and pharmaceutical composition containing the same
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
HK1028191A (en) Composition comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazo lidine-2,4-dione
HK1032905A (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
HK1068883A (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical compositions comprising the same
IL160144A0 (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2, 4-dione
HK1055294A (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical